160 related articles for article (PubMed ID: 12014712)
1. Does iron reduction improve sustained viral responses to interferon monotherapy in hepatitis C patients? Maybe, but is this the right question?
Shedlofsky SI
Am J Gastroenterol; 2002 May; 97(5):1093-6. PubMed ID: 12014712
[No Abstract] [Full Text] [Related]
2. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
[TBL] [Abstract][Full Text] [Related]
3. The interferon sensitivity determining region: all hepatitis C virus isolates are not the same.
Herion D; Hoofnagle JH
Hepatology; 1997 Mar; 25(3):769-71. PubMed ID: 9049233
[No Abstract] [Full Text] [Related]
4. Mechanism of action of interferon and ribavirin in treatment of hepatitis C.
Feld JJ; Hoofnagle JH
Nature; 2005 Aug; 436(7053):967-72. PubMed ID: 16107837
[TBL] [Abstract][Full Text] [Related]
5. [Fluctuation of hepatitis C virus quasispecies with interferon treatment and interferon-resistant variants in hepatitis C virus 1b].
Sakuma I; Enomoto N; Asahina Y; Kurosaki M; Sato C
Nihon Rinsho; 1995 Sep; 53 Suppl(Pt 1):930-5. PubMed ID: 7563904
[No Abstract] [Full Text] [Related]
6. Novel interferons for treatment of hepatitis C virus.
Clark V; Nelson DR
Clin Liver Dis; 2009 Aug; 13(3):351-63. PubMed ID: 19628153
[TBL] [Abstract][Full Text] [Related]
7. Future therapies for hepatitis C.
Pawlotsky JM; Gish RG
Antivir Ther; 2006; 11(4):397-408. PubMed ID: 16856613
[TBL] [Abstract][Full Text] [Related]
8. Interferon-based hepatitis C treatment in patients with pre-existing severe mental illness and substance use disorders.
Freedman K; Nathanson J
Expert Rev Anti Infect Ther; 2009 Apr; 7(3):363-76. PubMed ID: 19344248
[TBL] [Abstract][Full Text] [Related]
9. [Current and future applications of viral clearance kinetics in the treatment of hepatitis C].
Buti M
Gastroenterol Hepatol; 2004 Feb; 27 Suppl 1():24-9. PubMed ID: 15195531
[No Abstract] [Full Text] [Related]
10. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
[TBL] [Abstract][Full Text] [Related]
11. Management of hepatitis C virus genotype 4.
Abdo AA; Lee SS
J Gastroenterol Hepatol; 2004 Nov; 19(11):1233-9. PubMed ID: 15482528
[TBL] [Abstract][Full Text] [Related]
12. Early prediction of hepatitis C virus (HCV) infection relapse in nonresponders to primary interferon therapy by means of HCV RNA whole-blood analysis.
Watkins-Riedel T; Ferenci P; Steindl-Munda P; Gschwantler M; Mueller C; Woegerbauer M
Clin Infect Dis; 2004 Dec; 39(12):1754-60. PubMed ID: 15578395
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of interferon resistance in hepatitis C.
Gretch D
Lancet; 2001 Nov; 358(9294):1662-4. PubMed ID: 11728538
[No Abstract] [Full Text] [Related]
14. Diagnosis and management of hepatitis C virus-infected children.
Jhaveri R
Pediatr Infect Dis J; 2011 Nov; 30(11):983-5. PubMed ID: 21997662
[No Abstract] [Full Text] [Related]
15. Novel hepatitis C drugs in current trials.
Kronenberger B; Welsch C; Forestier N; Zeuzem S
Clin Liver Dis; 2008 Aug; 12(3):529-55, viii. PubMed ID: 18625427
[TBL] [Abstract][Full Text] [Related]
16. Strategies for hepatitis C therapeutic intervention: now and next.
Tan SL; He Y; Huang Y; Gale M
Curr Opin Pharmacol; 2004 Oct; 4(5):465-70. PubMed ID: 15351350
[TBL] [Abstract][Full Text] [Related]
17. Therapy of hepatitis C in thalassemia: the influence of iron on achieving sustained viral response.
Alavian SM; Tabatabaei SV
Ann Hematol; 2010 Feb; 89(2):215-6. PubMed ID: 19590873
[No Abstract] [Full Text] [Related]
18. Prediction of relapse following treatment for hepatitis C: is whole blood more than the sum of its parts?
Shire N; Koziel MJ
Clin Infect Dis; 2004 Dec; 39(12):1761-3. PubMed ID: 15578396
[No Abstract] [Full Text] [Related]
19. A mutational shift from domain III to II in the internal ribosome entry site of hepatitis C virus after interferon-ribavirin therapy.
Ogata K; Kashiwagi T; Iwahashi J; Hara K; Honda H; Ide T; Kumashiro R; Kohara M; Sata M; Watanabe H; Hamada N
Arch Virol; 2008; 153(8):1575-9. PubMed ID: 18592133
[TBL] [Abstract][Full Text] [Related]
20. Acute hepatitis C: prevention and treatment.
Ozaras R; Tahan V
Expert Rev Anti Infect Ther; 2009 Apr; 7(3):351-61. PubMed ID: 19344247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
